Welcome!

News Feed Item

Treatment Algorithms: Postherpetic Neuralgia - Lyrica forms the cornerstone of treatment for postherpetic neuralgia

NEW YORK, Dec. 17, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Treatment Algorithms: Postherpetic Neuralgia – Lyrica forms the cornerstone of treatment for postherpetic neuralgia

http://www.reportlinker.com/p01055536/Treatment-Algorithms-Postherpetic-Neuralgia-–-Lyrica-forms-the-cornerstone-of-treatment-for-postherpetic-neuralgia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Prescribing trends reveal that patients with PHN are typically initiated on monotherapy. Since no single therapy provides sufficient efficacy, physicians increasingly turn to combination therapy at later lines of treatment to optimize patient outcomes. Lyrica (pregabalin; Pfizer) leads the market, with the recent market entrant Gralise (extended-release gabapentin) struggling to make an impact.Gain insight into patient presentation, diagnosis, and treatment rates and understand which physician types are responsible for management of PHN.Quantify the PHN population across the seven major markets by pain severity (mild, moderate, and severe).Understand which drug treatments are the most commonly prescribed and how this differs across line of therapy and geographic region.Analyze the class, formulation, and brand prescribing trends in the seven major markets.Understand the response rate of patients across three lines of therapy and rates of progression from first to second and third lines of therapy.Following first-line therapy, combination therapies become the mainstay of treatment regimens for the management of PHN, as physicians attempt to optimize therapeutic outcomes. Therefore positioning treatments as adjuvant therapy represents a key opportunity for drug developers.With the vast majority of patients prescribed anticonvulsants as first-line therapy, this treatment class represents the key competition to prospective market entrants. Widespread, off-label prescribing of antidepressants also represents a significant competitive barrier within the PHN market.Lyrica (pregabalin; Pfizer) is the leading brand in the PHN market. Generally, branded products are well received in the market, accounting for the majority of treatments prescribed at first-line therapy.What drugs are the most commonly prescribed for the management of PHN in each of the seven major markets?What are the current PHN market dynamics and the competitive landscape in terms of patient numbers?How can drug developers optimize patient share and position new products appropriately within the PHN market?Which physician types are primarily responsible for PHN prescribing decisions and are therefore key targets for marketing efforts for PHN treatments?What proportion of patients responds to first-line therapy and what proportion progress to second and third lines of therapy?

OVERVIEW

Summary

EXECUTIVE SUMMARY

Datamonitor key findings

COUNTRY TREATMENT TREES

Introduction to treatment trees

Seven major markets

US

Japan

France

Germany

Italy

Spain

UK

DISEASE DEFINITION AND DIAGNOSIS

Disease definition

Etiology

Postherpetic neuralgia results from nerve damage caused by the herpes zoster virus

There are three key points of influence in the prevention of postherpetic neuralgia

Symptoms

Presentation and diagnosis

Less than two thirds of individuals with symptoms of postherpetic neuralgia present to a physician

Of individuals presenting to physicians with symptoms of PHN, 58% receive a diagnosis of PHN

Treatment rates

Across the seven major markets, 37% of diagnosed PHN patients do not receive pharmacological treatment

Influences on diagnosis and treatment rates

Identification of patients at risk of developing PHN is key to capturing the potential treatment market

Referral patterns

Patients with PHN are predominantly managed by primary care physicians/general practitioners

PATIENT SEGMENTATION

Severity of postherpetic neuralgia

The majority of patients with postherpetic neuralgia suffer from moderate to severe pain

Symptoms associated with pain in PHN

Burning sensation, shooting pain, and interrupted sleep are the key pain-associated symptoms in PHN

CURRENT TREATMENT OPTIONS

Overview of drug classes

Only five patented products are indicated for the treatment of postherpetic neuralgia

Anticonvulsants

Antidepressants

Opioids

Topical treatments

PRESCRIBING TRENDS

Class trends

Anticonvulsants are the most commonly prescribed drug class for PHN across all lines of therapy

Across the seven major markets antidepressants are frequently prescribed off-label for PHN

The US has the highest level of opioid prescribing for postherpetic neuralgia

Poor perception of efficacy leaves local anesthetics as the fourth most frequently prescribed drug class

Anxiolytic and antiarrhythmic treatments are not widely prescribed for the management of PHN

Formulation trends

Oral treatments dominate the treatment of postherpetic neuralgia at all lines of therapy

Combination therapy trends

Combination therapy is the mainstay at second and third-line therapy in order to optimize patient outcomes

Prescribing of brands versus generics

Branded products are favored for the first-line management of PHN

Changes in therapy

Lyrica monotherapy dominates the market as the top therapeutic option across all lines of therapy

Lyrica continues to dominate at second-line therapy

Treatments struggle to dominate later lines of therapy amid a vast range of different therapeutic options

Lidoderm and Lyrica provide models of successful PHN treatments in the US market

Patients with PHN increasingly spend longer on second and third-line therapy

Treatment outcomes

Response to therapy

Progression through lines of therapy

Compliance to therapy

BIBLIOGRAPHY

Journal papers

Websites

APPENDIX A

Physician research methodology

Physician sample breakdown

The survey questionnaire

Screener

APPENDIX B

Contributing experts

Conferences attended

TABLES

Table: Summary of drug classes and molecules used for the treatment of postherpetic neuralgia, 2012

Table: The proportion of patients across the seven major markets receiving monotherapy or combination therapy, across different lines of therapy, in the seven major markets, 2012

Table: The top 20 first-line treatments for postherpetic neuralgia across the seven major markets and the proportion of patients receiving these therapies in the individual markets, 2012

Table: The top 20 second-line treatments for postherpetic neuralgia across the seven major markets and the proportion of patients receiving these therapies in the individual markets, 2012

Table: The top 20 third-line treatments for postherpetic neuralgia across the seven major markets and the proportion of patients receiving these therapies in the individual markets, 2012

Table: Treatment response among patients with postherpetic neuralgia across the seven major markets, 2012

Table: Physicians surveyed regarding neuropathic pain across the seven major markets, 2012

FIGURES

Figure: Postherpetic neuropathic pain treatment algorithm in the US, 2012

Figure: Postherpetic neuropathic pain treatment algorithm in Japan, 2012

Figure: Postherpetic neuropathic pain treatment algorithm in France, 2012

Figure: Postherpetic neuropathic pain treatment algorithm in Germany, 2012

Figure: Postherpetic neuropathic pain treatment algorithm in Italy, 2012

Figure: Postherpetic neuropathic pain treatment algorithm in Spain, 2012

Figure: Postherpetic neuropathic pain treatment algorithm in the UK, 2012

Figure: Etiology of postherpetic neuralgia

Figure: Common sites for shingles and subsequent postherpetic neuralgia

Figure: Percentage of individuals with the symptoms of postherpetic neuralgia presenting to physicians, 2012

Figure: The diagnosis rate of individuals presenting to physicians with the symptoms of postherpetic neuralgia, 2012

Figure: The percentage of patients diagnosed with postherpetic neuralgia receiving pharmacological treatment, 2012

Figure: A screenshot of patient-centric educational material regarding postherpetic neuralgia, produced by Depomed, 2011

Figure: Percentage of postherpetic neuralgia patients across the seven major markets who are managed by different healthcare professionals during patient presentation, diagnosis, treatment, and management, 2012

Figure: Patient segmentation by severity of postherpetic neuralgia pain, across the seven major markets, 2012

Figure: Percentage of patients experiencing pain associated with the symptoms of postherpetic neuralgia, 2012

Figure: The impact of postherpetic neuralgia symptoms on patients, as rated by surveyed physicians, 2012

Figure: Proportion of patients with postherpetic neuralgia receiving different classes of therapy at three lines of therapy, across the seven major markets, 2012

Figure: The percentage of patients receiving each drug class as first-line therapy across the seven major markets, 2012

Figure: The relative proportion of therapies, by formulation, that patients are prescribed for the management of postherpetic neuralgia, 2012

Figure: The percentage of patients with postherpetic neuralgia receiving combination or monotherapy across different lines of therapy, in the seven major markets, 2012

Figure: The relative proportion of branded versus generic products prescribed for the first-line management of postherpetic neuralgia across the seven major markets, 2012

Figure: The relative percentage of branded or generic drug therapies prescribed to patients in the seven major markets, Spain, and the UK, 2012

Figure: The percentage of patients receiving branded products as first-line therapy, by drug class, across the seven major markets, 2012

Figure: The top 10 first-line treatments for postherpetic neuralgia across the seven major markets and the proportion of patients receiving these therapies in the individual markets, 2012

Figure: The top 10 second-line treatments for postherpetic neuralgia across the seven major markets and the proportion of patients receiving these therapies in the individual markets, 2012

Figure: The top 10 third-line treatments for postherpetic neuralgia across the seven major markets and the proportion of patients receiving these therapies in the individual markets, 2012

Figure: The proportion of patients receiving key FDA-approved therapies, either as monotherapy or combination therapy, for the management of postherpetic neuralgia, across all lines of therapy in the US, 2012

Figure: The mean number of weeks patients with postherpetic neuralgia spend on first, second, and third-line therapy, across the seven major markets, 2012

Figure: Percentage of postherpetic neuralgia patients responding to first-line therapy across the seven major markets, 2012

Figure: The percentage of patients who progress through three lines of pharmacotherapy across the seven major markets, 2012

Figure: Mean compliance rate across the seven major markets, by type of therapeutic regimen, 2012

Figure: Reasons for patients' non-compliance to therapy in neuropathic pain, 2012

Figure: First-line treatment of postherpetic neuralgia

Figure: Second-line treatment of postherpetic neuralgia

Figure: Third-line treatment of postherpetic neuralgia

Companies Mentioned

Choices, Devoteam SA, GlaxoSmithKline Plc, Hutchison 3G UK Limited, Schindler Holding Ltd.

To order this report:Therapy Industry: Treatment Algorithms: Postherpetic Neuralgia – Lyrica forms the cornerstone of treatment for postherpetic neuralgia

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Large scale deployments present unique planning challenges, system commissioning hurdles between IT and OT and demand careful system hand-off orchestration. In his session at @ThingsExpo, Jeff Smith, Senior Director and a founding member of Incenergy, will discuss some of the key tactics to ensure delivery success based on his experience of the last two years deploying Industrial IoT systems across four continents.
Most organizations prioritize data security only after their data has already been compromised. Proactive prevention is important, but how can you accomplish that on a small budget? Learn how the cloud, combined with a defense and in-depth approach, creates efficiencies by transferring and assigning risk. Security requires a multi-defense approach, and an in-house team may only be able to cherry pick from the essential components. In his session at 19th Cloud Expo, Vlad Friedman, CEO/Founder o...
"We host and fully manage cloud data services, whether we store, the data, move the data, or run analytics on the data," stated Kamal Shannak, Senior Development Manager, Cloud Data Services, IBM, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
CenturyLink has announced that application server solutions from GENBAND are now available as part of CenturyLink’s Networx contracts. The General Services Administration (GSA)’s Networx program includes the largest telecommunications contract vehicles ever awarded by the federal government. CenturyLink recently secured an extension through spring 2020 of its offerings available to federal government agencies via GSA’s Networx Universal and Enterprise contracts. GENBAND’s EXPERiUS™ Application...
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
"We view the cloud not really as a specific technology but as a way of doing business and that way of doing business is transforming the way software, infrastructure and services are being delivered to business," explained Matthew Rosen, CEO and Director at Fusion, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and shared the must-have mindsets for removing complexity from the develo...
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
SYS-CON Events announced today that MangoApps will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. MangoApps provides modern company intranets and team collaboration software, allowing workers to stay connected and productive from anywhere in the world and from any device.
“We're a global managed hosting provider. Our core customer set is a U.S.-based customer that is looking to go global,” explained Adam Rogers, Managing Director at ANEXIA, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
"This week we're really focusing on scalability, asset preservation and how do you back up to the cloud and in the cloud with object storage, which is really a new way of attacking dealing with your file, your blocked data, where you put it and how you access it," stated Jeff Greenwald, Senior Director of Market Development at HGST, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
The IETF draft standard for M2M certificates is a security solution specifically designed for the demanding needs of IoT/M2M applications. In his session at @ThingsExpo, Brian Romansky, VP of Strategic Technology at TrustPoint Innovation, explained how M2M certificates can efficiently enable confidentiality, integrity, and authenticity on highly constrained devices.
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...
In today's uber-connected, consumer-centric, cloud-enabled, insights-driven, multi-device, global world, the focus of solutions has shifted from the product that is sold to the person who is buying the product or service. Enterprises have rebranded their business around the consumers of their products. The buyer is the person and the focus is not on the offering. The person is connected through multiple devices, wearables, at home, on the road, and in multiple locations, sometimes simultaneously...
“delaPlex Software provides software outsourcing services. We have a hybrid model where we have onshore developers and project managers that we can place anywhere in the U.S. or in Europe,” explained Manish Sachdeva, CEO at delaPlex Software, in this SYS-CON.tv interview at @ThingsExpo, held June 7-9, 2016, at the Javits Center in New York City, NY.